BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MGC Diagnostics Corporation Announces Partnership With Frontera Strategies, LP


2/27/2013 9:46:08 AM

SAINT PAUL, Minn., Feb. 27, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced it has entered into a partnership with Frontera Strategies, LP ("Frontera"), the leading provider of in-office cardiac, pulmonary, vascular and neurological testing services. As a result of this partnership, Frontera has agreed to purchase new cardiopulmonary diagnostic equipment with customized systems developed and designed by MGC Diagnostics to better meet the demanding requirements of Frontera's mobile testing procedures. Based in Irving, Texas, Frontera Strategies has been recognized by Modern Healthcare as one of the "Best Places to Work" in the healthcare industry.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

MGC Diagnostics, ranked 'Best-In-Class' by MD Buyline's User Satisfaction Report, is focused on providing non-invasive diagnostic systems with unmatched service and support throughout the U.S. and internationally.

Kai Pinkerton, Clinical Operations Manager of Frontera, commented "We chose MGC Diagnostics because of their product quality, service excellence and attractive company culture. Clinically we were pleased with the products and MGC Diagnostics was flexible enough to work out a winning solution for us. At Frontera the experience for our patients and customers is our number one priority. Partnering with MGC Diagnostics, who leads their industry in service excellence, was a natural fit."

Richard Baker, Co-founder and Partner of Frontera, added "As a leader in mobile diagnostic services, we are excited to partner with MGC Diagnostics to better serve our customers and their patients within the Oklahoma and Texas markets. Our goal is to be a thought leader in driving down healthcare costs and we are looking for ways to bring better, more cost efficient diagnostic testing to the marketplace."

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "We are pleased to have been chosen by Frontera to assist them in maintaining a leadership role in mobile testing. As part of our efforts to improve patient outcomes and reduce healthcare costs, we remain committed to providing innovative diagnostic equipment to mobile testing services focused at physicians' offices, as well as at traditional healthcare facilities."

About Frontera Strategies
Frontera is the leading provider of in-office cardiac, pulmonary, vascular and neurological testing services. With more than 2,000 partners across Texas and Oklahoma, Frontera serves physicians in Dallas, Ft. Worth, Austin, Houston, San Antonio, Lubbock, Amarillo, Oklahoma City and Tulsa. Frontera was founded in 2001 by partners Richard Baker, Nate Nelson and Ches Williams. For more information, please visit: http://www.teamfrontera.com.

About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forwardlooking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forwardlooking statements, the Company claims the protection of the safe harbor for forwardlooking statements contained in federal securities laws. These forwardlooking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forwardlooking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe Diaz


MGC Diagnostics Corporation

Lytham Partners, LLC


Chief Executive Officer

(602) 889-9700


(651) 484-4874

mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES